Publications by authors named "L Sellami"
Article Synopsis
- - The Dépistage Cognitif de Québec (DCQ) was created to detect atypical dementia, addressing the lack of specific cognitive screening tools and reducing delays in diagnosis and care.
- - A study in Canada and the U.S. involving 260 English-speaking participants validated the English version of the DCQ, showing strong correlations with other cognitive assessments and high reliability across testing conditions.
- - The English DCQ effectively identifies various atypical dementias, making it a quick, 20-minute alternative to comprehensive neuropsychological tests, with standardized scores based on age and education levels.
Article Synopsis
- Pathogenic heterozygous mutations in the GRN gene are a significant cause of frontotemporal dementia (FTD), leading to lower levels of the progranulin protein in biofluids, which has sparked therapeutic trials aimed at increasing these levels.
- A systematic review of literature on biofluid PGRN concentrations included data from 7071 individuals, primarily focusing on plasma PGRN levels derived from a single assay type, which accounted for variations based on mutation type, age, sex, and clinical diagnosis.
- Key findings established specific concentration cut-offs for plasma (74.8 ng/mL) and CSF (3.43 ng/mL) and indicated that plasma PGRN levels vary by mutation type,
The Woven EndoBridge (WEB) is an intra-aneurysmal flow disruptor designed for the treatment of broad-based arterial aneurysms with a high safety and effectiveness profile. It does not require concomitant antiplatelet therapy compared to other devices such as flow diverters or intracranial stents. Innominate artery pseudoaneurysms are a rare consequence of blunt traumatic injury, infection, or atherosclerotic disease.
View Article and Find Full Text PDFBackground And Objectives: variants are a frequent cause of familial frontotemporal dementia (FTD). Monitoring disease progression in asymptomatic carriers of genetic variants is a major challenge in delivering preventative therapies before clinical onset. This study aimed to assess the usefulness of fluorodeoxyglucose (FDG)-PET in identifying metabolic changes in presymptomatic carriers (PS-+) and to trace their longitudinal progression.
View Article and Find Full Text PDF